StockNews.com Upgrades ICU Medical (NASDAQ:ICUI) to Buy

ICU Medical (NASDAQ:ICUI) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

Several other brokerages also recently weighed in on ICUI. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. KeyCorp increased their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Raymond James upped their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Trading Up 0.7 %

ICU Medical stock opened at $168.84 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm’s 50 day moving average price is $176.43 and its 200-day moving average price is $144.63. ICU Medical has a 1 year low of $83.09 and a 1 year high of $196.26. The stock has a market cap of $4.13 billion, a P/E ratio of -36.95 and a beta of 0.66.

Insider Buying and Selling

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. This trade represents a 10.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock worth $6,573,496 in the last three months. 6.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in shares of ICU Medical during the second quarter valued at about $32,000. Hexagon Capital Partners LLC increased its stake in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares in the last quarter. Allworth Financial LP increased its stake in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares in the last quarter. EntryPoint Capital LLC raised its holdings in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.